BEONE MEDICINES LTD-ADR (ONC) Stock Fundamental Analysis
USA - NASDAQ:ONC - US07725L1026 - ADR
368.36 USD
-9.11 (-2.41%)
363.45 USD
-4.91 (-1.33%)
Taking everything into account, ONC scores 5 out of 10 in our fundamental rating. ONC was compared to 531 industry peers in the Biotechnology industry. The financial health of ONC is average, but there are quite some concerns on its profitability. ONC is growing strongly while it also seems undervalued. This is an interesting combination
1. Profitability
1.1 Basic Checks
In the past year ONC was profitable.
ONC had a positive operating cash flow in the past year.
In the past 5 years ONC always reported negative net income.
In the past 5 years ONC always reported negative operating cash flow.
1.2 Ratios
ONC has a Return On Assets of -3.68%. This is amongst the best in the industry. ONC outperforms 87.57% of its industry peers.
ONC's Return On Equity of -6.15% is amongst the best of the industry. ONC outperforms 89.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| ROIC | N/A |
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ONC has a Gross Margin of 85.37%. This is amongst the best in the industry. ONC outperforms 87.95% of its industry peers.
ONC's Gross Margin has been stable in the last couple of years.
ONC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
2. Health
2.1 Basic Checks
ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ONC has been increased compared to 5 years ago.
Compared to 1 year ago, ONC has a worse debt to assets ratio.
2.2 Solvency
ONC has an Altman-Z score of 8.77. This indicates that ONC is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.77, ONC belongs to the top of the industry, outperforming 82.11% of the companies in the same industry.
The Debt to FCF ratio of ONC is 5.47, which is a neutral value as it means it would take ONC, 5.47 years of fcf income to pay off all of its debts.
ONC's Debt to FCF ratio of 5.47 is amongst the best of the industry. ONC outperforms 91.90% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ONC is not too dependend on debt financing.
ONC has a Debt to Equity ratio of 0.26. This is in the lower half of the industry: ONC underperforms 69.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 8.77 |
ROIC/WACCN/A
WACC4.81%
2.3 Liquidity
ONC has a Current Ratio of 1.94. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
ONC has a worse Current ratio (1.94) than 76.46% of its industry peers.
A Quick Ratio of 1.71 indicates that ONC should not have too much problems paying its short term obligations.
ONC has a Quick ratio of 1.71. This is in the lower half of the industry: ONC underperforms 79.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 217.98% over the past year.
The Revenue has grown by 47.67% in the past year. This is a very strong growth!
The Revenue has been growing by 55.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)217.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%
3.2 Future
Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 95.39% on average per year.
ONC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.95% yearly.
EPS Next Y128.58%
EPS Next 2Y69.11%
EPS Next 3Y51.39%
EPS Next 5Y95.39%
Revenue Next Year40.27%
Revenue Next 2Y31.06%
Revenue Next 3Y25.91%
Revenue Next 5Y18.95%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.96, the valuation of ONC can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of ONC indicates a rather cheap valuation: ONC is cheaper than 98.31% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.91, ONC is valued rather cheaply.
A Price/Forward Earnings ratio of 59.56 indicates a quite expensive valuation of ONC.
Based on the Price/Forward Earnings ratio, ONC is valued cheaper than 89.27% of the companies in the same industry.
ONC is valuated expensively when we compare the Price/Forward Earnings ratio to 34.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.96 | ||
| Fwd PE | 59.56 |
4.2 Price Multiples
ONC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ONC is cheaper than 90.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 215.2 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ONC's earnings are expected to grow with 51.39% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y69.11%
EPS Next 3Y51.39%
5. Dividend
5.1 Amount
No dividends for ONC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
368.36
-9.11 (-2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners33.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change5.79%
Market Cap40.76B
Revenue(TTM)32.74B
Net Income(TTM)-1.65B
Analysts82.67
Price Target334.23 (-9.27%)
Short Float %17.51%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.55
Dividend Growth(5Y)N/A
DP-30.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2148.49%
Min EPS beat(2)1187.13%
Max EPS beat(2)3109.85%
EPS beat(4)3
Avg EPS beat(4)1518.68%
Min EPS beat(4)-22.81%
Max EPS beat(4)3109.85%
EPS beat(8)4
Avg EPS beat(8)536.4%
EPS beat(12)5
Avg EPS beat(12)344.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.52%
Min Revenue beat(2)-1.25%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-1.25%
Max Revenue beat(4)6.29%
Revenue beat(8)7
Avg Revenue beat(8)13.13%
Revenue beat(12)11
Avg Revenue beat(12)13.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.93%
PT rev (3m)3.63%
EPS NQ rev (1m)-0.74%
EPS NQ rev (3m)1248.94%
EPS NY rev (1m)32.17%
EPS NY rev (3m)236.3%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)9.73%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.96 | ||
| Fwd PE | 59.56 | ||
| P/S | 8.84 | ||
| P/FCF | 215.2 | ||
| P/OCF | 83.24 | ||
| P/B | 10.77 | ||
| P/tB | 11.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)61.81
EY16.78%
EPS(NY)6.18
Fwd EY1.68%
FCF(TTM)1.71
FCFY0.46%
OCF(TTM)4.43
OCFY1.2%
SpS41.69
BVpS34.2
TBVpS32.62
PEG (NY)0.05
PEG (5Y)N/A
Graham Number218.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% | ||
| FCFM | 4.11% |
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score6
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | 8.77 |
F-Score6
WACC4.81%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)217.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
EPS Next Y128.58%
EPS Next 2Y69.11%
EPS Next 3Y51.39%
EPS Next 5Y95.39%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%
Revenue Next Year40.27%
Revenue Next 2Y31.06%
Revenue Next 3Y25.91%
Revenue Next 5Y18.95%
EBIT growth 1Y89.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year178.04%
EBIT Next 3Y67.31%
EBIT Next 5Y60.12%
FCF growth 1Y110.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y136.32%
OCF growth 3YN/A
OCF growth 5YN/A
BEONE MEDICINES LTD-ADR / ONC FAQ
What is the ChartMill fundamental rating of BEONE MEDICINES LTD-ADR (ONC) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ONC.
Can you provide the valuation status for BEONE MEDICINES LTD-ADR?
ChartMill assigns a valuation rating of 7 / 10 to BEONE MEDICINES LTD-ADR (ONC). This can be considered as Undervalued.
How profitable is BEONE MEDICINES LTD-ADR (ONC) stock?
BEONE MEDICINES LTD-ADR (ONC) has a profitability rating of 3 / 10.
Can you provide the financial health for ONC stock?
The financial health rating of BEONE MEDICINES LTD-ADR (ONC) is 5 / 10.
Can you provide the dividend sustainability for ONC stock?
The dividend rating of BEONE MEDICINES LTD-ADR (ONC) is 0 / 10 and the dividend payout ratio is -30.61%.